
    
      The SPIRIT II trial was a randomized, single blind, active control, multi-center clinical
      evaluation. Subject eligibility criteria were similar to SPIRIT III and enrollment duration
      overlapped between studies. In this study, 300 subjects (3:1 randomization XIENCE V® EECSS:
      TAXUS™ PECSS were enrolled at 31 sites outside the United States. The primary endpoint was
      in-stent late loss at 6 months. Secondary endpoints included clinical outcomes at months 1,
      6, and 9 months and 1, 2, 3, 4 and 5 years; angiographic results at 6 months and 2 years; and
      IVUS results at 6 months and 2 years. Follow-up through 3 years is currently available.
    
  